Press Resease

Diabetic Retinopathy Market by Type (Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy) and by Management (Vitrectomy, Anti-VEGF Therapy, Laser Surgery, and Intraocular Steroid Injection): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017– 2024

Published Date: 06-Nov-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3504 Status : Published

Global diabetic retinopathy market expected to generate revenue of around USD 9.3 billion by the end of 2024, growing at a CAGR of around 6.5% between 2018 and 2024. The increasing technological advancements combined with 3D technology are projected to foster the growth of the market.

Description

The report covers forecast and analysis for the diabetic retinopathy market on a global and regional level. The study provides historical data from 2015along with a forecast from 2018to 2024based on revenue (USD Billion). The study includes drivers and restraints for the diabetic retinopathy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the diabetic retinopathy market on a global and regional level.

In order to give the users of this report a comprehensive view on the diabetic retinopathy market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Type segment is benchmarked based on their market size, growth rate, and general attractiveness.

Diabetic-Retinopathy-Market

The report provides company market share analysis in order to give a broader overview of the key players in the diabetic retinopathy market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new type launch, agreements, partnerships, collaborations & joint ventures, research& development, and regional expansion of major participants involved in the diabetic retinopathy market on a global and regional basis.

The study provides a decisive view on the diabetic retinopathy market by segmenting the market based on type, management, and region. The segments have been analyzed based on present and future trends and the market is estimated from 2018to 2024. Based on the type, diabetic retinopathy market has been segmented into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy segment holds the majority market share, due to the rising number of diabetic retinopathy patients and increasing awareness. The management segment includes vitrectomy, anti-VEGF therapy, laser surgery, and intraocular steroid injection. Anti-VEGF therapy segment holds the majority share of the management segment, due to its multiple benefits when compared to other therapies.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes the demand for diabetic retinopathy based on individual segments and types in all regions and countries.

The report also includes detailed profiles of end-players, Regeneron Pharmaceuticals, Novartis, Allergan, Genentech, Bayer AG, Aerpio Pharmaceuticals, BCN Peptides, Ampio Pharmaceuticals, ThromboGenics, Alimera Sciences, and Kowa Company, among others.

This report segments the global diabetic retinopathy market as follows:

Global Diabetic Retinopathy Market: By Type

  • Non-Proliferative Diabetic Retinopathy
  • Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market: By Management

  • Vitrectomy
  • Anti-VEGF Therapy
  • Laser Surgery
  • Intraocular Steroid Injection

Global Diabetic Retinopathy Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Table Of Content

  • Chapter 1.    Introduction
    • 1.1.    Report description and scope
    • 1.2.    Research scope 
    • 1.3.    Research methodology
      • 1.3.1.    Market research process
      • 1.3.2.    Market research methodology
  •  
  • Chapter 2.    Executive Summary
    • 2.1.    Global Diabetic Retinopathy market, 2017–2024(USD Billion)
    • 2.2.    Global Diabetic Retinopathy market: Snapshot
  •  
  • Chapter 3.    Diabetic Retinopathy Market - Dynamics 
    • 3.1.    Introduction 
    • 3.2.    Market drivers
      • 3.2.1.    Global Diabetic Retinopathy market drivers: Impact analysis
      • 3.2.2.    Growing number of people from baby boomer generation worldwide
      • 3.2.3.    Rising occurrence of diabetes due to sedentary lifestyle and unhealthy diet
    • 3.3.    Market Restraints
      • 3.3.1.    Lack of skilled ophthalmologists
      • 3.3.2.    Non-availability of insurance facilities
    • 3.4.    Opportunities
      • 3.4.1.    Efforts taken by various governments and non-government organizations to increase awareness regarding diabetic retinopathy
    • 3.5.    Porter’s five forces analysis
      • 3.5.1.    Bargaining power of suppliers 
      • 3.5.2.    Bargaining power of buyers
      • 3.5.3.    The threat from new entrants
      • 3.5.4.    The threat from new substitutes
      • 3.5.5.    Degree of competition                 
    • 3.6.    Market attractiveness analysis
      • 3.6.1.    Market attractiveness analysis, by type segment
      • 3.6.2.    Market attractiveness analysis, by management
  •  
  • Chapter 4.    Global Diabetic Retinopathy Market – Competitive Landscape
    • 4.1.    Company Market Share Analysis
      • 4.1.1.    Global Diabetic Retinopathy market: company market share, 2017
    • 4.2.    Strategic Development
      • 4.2.1.    Acquisitions & Mergers
      • 4.2.2.    New Type Launch
      • 4.2.3.    Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4.    Research and Development, Regional Expansion
  •  
  • Chapter 5.    Global Diabetic Retinopathy Market – Type Segment Analysis
    • 5.1.    Global Diabetic Retinopathy market: Type overview 
      • 5.1.1.    Global Diabetic Retinopathy market revenue share, by Type, 2017 and 2024
    • 5.2.    Non-Proliferative Diabetic Retinopathy
      • 5.2.1.    Global Diabetic Retinopathy market for Non-Proliferative Diabetic Retinopathy, 2017 – 2024(USD Billion)
    • 5.3.    Proliferative Diabetic Retinopathy
      • 5.3.1.    Global Diabetic Retinopathy market for Proliferative Diabetic Retinopathy, 2017 – 2024(USD Billion)
  •  
  • Chapter 6.    Global Diabetic Retinopathy Market – Management Segment Analysis
    • 6.1.    Global Diabetic Retinopathy market: Management overview 
      • 6.1.1.    Global Diabetic Retinopathy market revenue share, by Management, 2017 and 2024
    • 6.2.    Vitrectomy
      • 6.2.1.    Global Diabetic Retinopathy market for Vitrectomy, 2017 – 2024 (USD Billion)
    • 6.3.    Anti-VEGF Therapy
      • 6.3.1.    Global Diabetic Retinopathy market for Anti-VEGF Therapy, 2017 – 2024 (USD Billion)
    • 6.4.    Laser Surgery
      • 6.4.1.    Global Diabetic Retinopathy market for Laser Surgery, 2017 – 2024 (USD Billion)
    • 6.5.    Intraocular Steroid Injection
      • 6.5.1.    Global Diabetic Retinopathy market for Intraocular Steroid Injection, 2017 – 2024 (USD Billion)
  •  
  • Chapter 7.    Global Diabetic Retinopathy Market – Regional Segment Analysis 
    • 7.1.    Global Diabetic Retinopathy market: Regional overview 
      • 7.1.1.    Global Diabetic Retinopathy market revenue share, by region, 2017 and 2024
    • 7.2.    North America 
      • 7.2.1.    North America Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
      • 7.2.2.    North America Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.2.3.    The U.S.
        • 7.2.3.1.    The U.S. Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.2.3.2.    The U.S. Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.2.4.    Canada
        • 7.2.4.1.    Canada Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.2.4.2.    Canada Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.2.5.    Rest of North America
        • 7.2.5.1.    Rest of North America Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.2.5.2.    Rest of North America Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
    • 7.3.    Europe 
      • 7.3.1.    Europe Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
      • 7.3.2.    Europe Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.3.    Germany
        • 7.3.3.1.    Germany Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.3.3.2.    Germany Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.4.    U.K.
        • 7.3.4.1.    U.K. Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.3.4.2.    U.K. Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.5.    France
        • 7.3.5.1.    France Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.3.5.2.    France Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.6.    Italy
        • 7.3.6.1.    Italy Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.3.6.2.    Italy Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.7.    Spain
        • 7.3.7.1.    Spain Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.3.7.2.    Spain Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.8.    Russia
        • 7.3.8.1.    Russia Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.3.8.2.    Russia Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.3.9.    Rest of Europe
        • 7.3.9.1.    Rest of Europe Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.3.9.2.    Rest of Europe Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
    • 7.4.    Asia Pacific 
      • 7.4.1.    Asia Pacific Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
      • 7.4.2.    Asia Pacific Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.4.3.    China
        • 7.4.3.1.    China Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.4.3.2.    China Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.4.4.    Japan  
        • 7.4.4.1.    Japan Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.4.4.2.    Japan Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.4.5.    India
        • 7.4.5.1.    India Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.4.5.2.    India Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.4.6.    Australia
        • 7.4.6.1.    Australia Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.4.6.2.    Australia Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.4.7.    Rest of Asia Pacific
        • 7.4.7.1.    Rest of Asia Pacific Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.4.7.2.    Rest of Asia Pacific Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
    • 7.5.    Latin America 
      • 7.5.1.    Latin America Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
      • 7.5.2.    Latin America Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.5.3.    Brazil
        • 7.5.3.1.    Brazil Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.5.3.2.    Brazil Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.5.4.    Mexico
        • 7.5.4.1.    Mexico Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.5.4.2.    Mexico Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.5.5.    Argentina
        • 7.5.5.1.    Argentina Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.5.5.2.    Argentina Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.5.6.    Rest of Latin America
        • 7.5.6.1.    Rest of Latin America Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
        • 7.5.6.2.    Rest of Latin America Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
    • 7.6.    Middle East and Africa
      • 7.6.1.    Middle East and Africa Diabetic Retinopathy market revenue, by Type, 2017 – 2024(USD Billion)
      • 7.6.2.    Middle East and Africa Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.6.3.    Saudi Arabia
        • 7.6.3.1.    Saudi Arabia Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.6.3.2.    Saudi Arabia Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.6.4.    UAE
        • 7.6.4.1.    UAE Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.6.4.2.    UAE Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.6.5.    South Africa
        • 7.6.5.1.    South Africa Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.6.5.2.    South Africa Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.6.6.    Qatar
        • 7.6.6.1.    Qatar Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.6.6.2.    Qatar Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
      • 7.6.7.    Rest of Middle East and Africa
        • 7.6.7.1.    Rest of Middle East and Africa Diabetic Retinopathy market revenue, by Type, 2017 – 2024 (USD Billion)
        • 7.6.7.2.    Rest of Middle East and Africa Diabetic Retinopathy market revenue, by Management, 2017 – 2024 (USD Billion)
  •  
  • Chapter 8.    Company Profile 
    • 8.1.    Regeneron Pharmaceuticals
      • 8.1.1.    Overview  
      • 8.1.2.    Financials  
      • 8.1.3.    Therapy portfolio 
      • 8.1.4.    Business strategy 
      • 8.1.5.    Recent developments 
    • 8.2.    Novartis
      • 8.2.1.    Overview  
      • 8.2.2.    Financials  
      • 8.2.3.    Therapy portfolio 
      • 8.2.4.    Business strategy 
      • 8.2.5.    Recent developments 
    • 8.3.    Allergan
      • 8.3.1.    Overview  
      • 8.3.2.    Financials  
      • 8.3.3.    Therapy portfolio 
      • 8.3.4.    Business strategy 
      • 8.3.5.    Recent developments 
    • 8.4.    Genentech
      • 8.4.1.    Overview  
      • 8.4.2.    Financials  
      • 8.4.3.    Therapy portfolio 
      • 8.4.4.    Business strategy 
      • 8.4.5.    Recent developments 
    • 8.5.    Bayer AG
      • 8.5.1.    Overview  
      • 8.5.2.    Financials  
      • 8.5.3.    Therapy portfolio 
      • 8.5.4.    Business strategy 
      • 8.5.5.    Recent developments
    • 8.6.    Aerpio Pharmaceuticals
      • 8.6.1.    Overview  
      • 8.6.2.    Financials  
      • 8.6.3.    Therapy portfolio 
      • 8.6.4.    Business strategy 
      • 8.6.5.    Recent developments
    • 8.7.    BCN Peptides
      • 8.7.1.    Overview  
      • 8.7.2.    Financials  
      • 8.7.3.    Therapy portfolio 
      • 8.7.4.    Business strategy 
      • 8.7.5.    Recent developments
    • 8.8.    Ampio Pharmaceuticals
      • 8.8.1.    Overview  
      • 8.8.2.    Financials  
      • 8.8.3.    Therapy portfolio 
      • 8.8.4.    Business strategy 
      • 8.8.5.    Recent developments
    • 8.9.    ThromboGenics
      • 8.9.1.    Overview  
      • 8.9.2.    Financials  
      • 8.9.3.    Therapy portfolio 
      • 8.9.4.    Business strategy 
      • 8.9.5.    Recent developments
    • 8.10.    Alimera Sciences
      • 8.10.1.    Overview  
      • 8.10.2.    Financials  
      • 8.10.3.    Therapy portfolio 
      • 8.10.4.    Business strategy 
      • 8.10.5.    Recent developments
    • 8.11.    Kowa Company
      • 8.11.1.    Overview  
      • 8.11.2.    Financials  
      • 8.11.3.    Therapy portfolio 
      • 8.11.4.    Business strategy 
      • 8.11.5.    Recent developments

Methodology

Free Analysis

Diabetic retinopathy is an eye disease in which the retina is damaged due to diabetes-related complications. People who have been suffering from diabetes for more than 20 years are at an elevated risk of diabetic retinopathy. Diabetic retinopathy does not have early warning signs. The continued high blood sugar levels lead to the damage of retinal blood vessels. The retinal blood vessels may swell and trickle. In certain cases, unusual blood vessels develop on the retina. Diabetic retinopathy can develop in people with type 1 or 2 diabetes. High sugar blood levels for a prolonged period of time leads to obstruction of small vessels that supply blood to the retina. Diabetic retinopathy progresses in four stages: mild non-proliferative retinopathy, moderate non-proliferative retinopathy, severe non-proliferative retinopathy, and proliferative diabetic retinopathy (PDR). In mild nonproliferative retinopathy, tiny balloon-like swelling occurs in retinal blood vessels. In moderate nonproliferative retinopathy, the vessels supplying blood to retina swell and change. Furthermore, these blood vessels might not carry the required blood. In severe non-proliferative retinopathy, more blood vessels are blocked, leading to deprivation of blood supply to the retina. Proliferative diabetic retinopathy is an advanced stage, where fragile, new blood vessels grow inside the retina and in the vitreous gel.

The severity of diabetic retinopathy can be minimized by taking constant eye check-ups, controlling blood sugar and blood pressure levels, and taking note of vision problems as and when they occur. Diagnosis of diabetic retinopathy is conducted through eye examinations, such as visual acuity test, pupil dilation, ophthalmoscopy, Fundus Fluorescein angiography (FFA), and Optical coherence tomography (OCT), among others. The eye care professionals examine the retina for initial symptoms of diabetic retinopathy.

Diabetic-Retinopathy-Market

As per the WHO estimates, the diabetic population has grown from 108 million adults in 1980 to approximately 422 million adults in 2014. Furthermore, diabetic prevalence globally has doubled from 4.7% in 1980 to around 8.5% in 2014. According to the Department of Assistive and Rehabilitative Services (DARS), around 78% diabetic retinopathy cases reported in 2013 might eventually lead to loss of vision. In U.K., diabetic retinopathy was the prominent cause of blindness in 2017, as per the Royal National Institute of Blind People (RNIB).

Growing baby boomer generation worldwide and rising occurrences of diabetes due to a sedentary lifestyle and an unhealthy diet are major factors driving the growth of the global diabetic retinopathy market. Furthermore, delayed diagnosis of diabetes, refusal for treatment, rising occurrences of vision loss due to diabetes, increasing healthcare expenditure, development of innovative treatments, and increasing research and development activities will further propel market growth. Various government and non-government organizations are trying to increase awareness regarding diabetic retinopathy and rapid advancements in the technology are acting as growth opportunities for the market players in the diabetic retinopathy market. However, lack of skilled ophthalmologists, non-availability of insurance facilities, and substandard primary infrastructure in developing regions might restrict the growth of the global diabetic retinopathy market.

The global diabetic retinopathy market is divided into type, management, and region. By type, the diabetic retinopathy market is bifurcated into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Non-proliferative diabetic retinopathy holds the majority market share, due to the rising number of diabetic retinopathy patients and increasing awareness. The management segment of the market includes vitrectomy, anti-VEGF therapy, laser surgery, and intraocular steroid injection. Anti-VEGF therapy segment holds the majority share of the management segment, due to its multiple benefits when compared to other therapies.

North America is projected to be the leading region in the forecast timeframe. The increasing prevalence of diabetic retinopathy and growing espousal of an unhealthy diet are driving the market growth in this region. Europe is projected to be the second largest market. The major growth factors include an increasing number of diabetic patients, rapid technological advancements, and increasing healthcare spending. The Asia Pacific is projected to propagate at a speedy rate in the forecast timeframe. Increasing geriatric population, growing diabetic population, and multiple governmental and non-governmental efforts will boost the market growth in this region. The Latin American market will develop at a significant rate in the forecast timeframe. The Middle Eastern and African countries are expected to experience moderate growth in the near future.

Some key players in the diabetic retinopathy market include Regeneron Pharmaceuticals, Novartis, Allergan, Genentech, Bayer AG, Aerpio Pharmaceuticals, BCN Peptides, Ampio Pharmaceuticals, ThromboGenics, Alimera Sciences, and Kowa Company, among others.

}